News
Quanterix Corporation and DestiNA Genomics to Collaborate in Effort to Transform microRNA Biomarker Detection
Breakthrough Research Published in PLOS ONE Demonstrates Quantitative, PCR-Free Detection of MicroRNA
Single Molecule MicroRNA Technology Proves Useful for Liver Toxicity Detection
LEXINGTON, Mass. and EDINBURGH, UK—July 5, 2017—
Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, and DestiNA Genomics Ltd, a manufacturer of patented reagents for nucleic acid detection, today announced that PLOS ONE has published a proof-of-concept single probe method for detecting microRNA biomarkers associated with liver toxicity.
Click here for full English press release. Click here for full Spanish press release.
Novel molecular assay based on ‘Single Nucleotide Fingerprints’ (SNF) for the diagnosis and monitoring of Trypanosomatids.
EDINBURGH, UK and GRANADA, Spain—July 21, 2017—
Researchers at the Centre for Genomics and Oncological Research (GENYO) located in Granada, Spain, in collaboration with DestiNA have developed a novel assay for the diagnosis and monitoring of Trypanosomatids. The method is based on a single-plex PCR, using specific primers that amplify a conserved homology region of Trypanosomatidae species. Amplified fragments are analyzed by DestiNA technology using two DestiNA probes and the four SMART nucleobases with MALDI-ToF for the unique pattern of ‘Single Nucleotide Fingerprints’ (SNF) for each species. This molecular assay can unequivocally identify the trypanosomiasis specie presents in a sample through their unique SNF pattern. The novel assay has been published in the peer-reviewed scientific journal Talanta.
DestiNA has adapted this MALDI-ToF based molecular assay to a colorimetric-based system using low density arrays within a spin-tube. This product provides an easy-to-use and cost effective tool with high sensitivity and specificity. The novel kit permits a rapid identification and differential diagnosis of Chagas disease and Leishmaniasis and monitoring therapeutic responses. For more information regarding this product, please see this page.
Salvatore Pernagallo presents the Integration of Luminex Platform with DestiNA “Single Nucleobase Labelling” technology for Direct Detection of Unlabelled Nucleic Acids.
xMAP® CONNECT 2016 Conference. Click here to download the abstract
Date 16th November 2016 | Location: Amsterdam (Netherlands)
DestiNA exhibits at MEDICA 2013. Microelectronic detector for miRNAs.
Date: 10th November 2013 | Location: Dusseldorf (Germany)
DestiNA feature on Canal Sur (Televisión Andaluza).
Dr Juan Jose Diaz Mochon presents DestiNA, new SMART Chemistry Platforms for Molecular Diagnostics, at SCIENION's workshop 2013.
Date: 12th – 13th September 2013 | Location: Berlin (Germany)
Juan Enrique Cruz Romera presents DestiNA to the Fundación Descubre.
Date: 28th January 2013 | Location: Granada (Spain)
Dr Salvatore Pernagallo presents DestiNA at Molecular Diagnostics Europe conference. ‘SMART Chemistry’ for Integrated Solutions in Molecular Diagnostics.
Date: 10th – 11th May 2012| Location: London (UK)
Dr Salvatore Pernagallo presents DestiNA at Lab-on-a-Chip European congress. Novel Biochip and Reagents for High Specificity Nucleic Acid Detections.
Date: 28th – 29th Mach 2012| Location: Edinburgh (UK)
DestiNA feature on Infinite Magazine. Annual Review of Research and Commercialization at the University of Edinburgh.
Date: 1st October 2011| Location: Edinburgh (UK)
DestiNA listed for the Annual Nexxus Life Science Award in Life Science.
Date: 1st August 2011| Location: Edinburgh (UK)
DestiNA attends the International Molecular Medicine Tri-Conference 2011.
Date: 23rd-25th February 2011| Location: San Francisco (USA)
DestiNA Technology in the BBC News. DNA test for inherited diseases.
Date: 16th February 2010| Location: Edinburgh (UK)
DestiNA in the Scotsman Front-Page. Half-hour DNA test to check for killer diseases.
Date: 16th February 2010| Location: Edinburgh (UK)
DestiNA in the STV News. Low-cost DNA test for genetic diseases could become reality.
Date: 16th February 2010| Location: Edinburgh (UK)
DestiNA presents at the Nexxus Event. DestiNA Genomics pitches at Scotland’s Premier Technology Investment Event.
Date: 17th November 2010| Location: Edinburgh (UK)